Moderna (NASDAQ:MRNA) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(3.81) by 69.03 percent. This is a 53.17 percent increase over losses of $(2.52) per share from the same period last year. The company reported quarterly sales of $389.000 million which beat the analyst consensus estimate of $227.969 million by 70.64 percent. This is a 260.19 percent increase over sales of $108.000 million the same period last year.